|Bid||0.00 x 0|
|Ask||0.00 x 0|
|Day's Range||32.83 - 33.35|
|52 Week Range||29.45 - 36.35|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.06%|
The world is full of model ETF portfolios, but we’re just starting to see the environmental, socially responsible and governance (ESG) filter as a consideration on many. The biggest recent news on this front was the development by robo-platform Betterment of an ESG version of its core portfolio last month.
Several of this year's top asset-gathering exchange traded funds are products focusing on developed market equities outside the U.S. Amid the rush to developed market ex-U.S. ETFs, another theme is becoming ...
Revenues for Sandoz are expected to report operational growth in 2Q17 following an increased demand for biopharmaceuticals.
Headquartered in Basel, Switzerland, Novartis (NVS) is a pharmaceutical company specializing in the research, development, manufacturing, and marketing of a broad range of healthcare products, mainly pharmaceuticals. ...
The Pharmaceuticals segment reported an operational growth of 4.0% and a 13.0% positive impact of foreign exchange, resulting in a rise of 17.0% in revenues.
A few of the segments AstraZeneca identifies as growth platforms include Respiratory products, new Cardiovascular and Metabolic Diseases products, and new Oncology products.
On January 6, 2017, Novartis announced the collaborative agreement with Ionis Pharmaceuticals (IONS) and its subsidiary Akcea Therapeutics.
[Editor’s Note: Due to a data error, an earlier version of this article suggested that the newly launched IDEV had taken over as the cheapest international developed-market equity ETF. In fact, the Schwab International Equity ETF (SCHF) remains the cheapest fund in that category, with an expense ratio of 0.06%. We apologize for the error, which has been corrected below.]